Balance Sheet
Accounts PayablesAccumulated ExpensesAssetsCash & EquivalentsCommon EquityCurrent AssetsCurrent LeasesLiabilities and Shareholders EquityLong-Term InvestmentsNon-Current AssetsOperating LeasesOther Accumulated ExpensesOther Non-Current AssetsPayablesPrepaid AssetsProperty, Plant & Equipment (Net)Retained EarningsShareholder's EquityTotal Current LiabilitiesTotal LiabilitiesTreasury Shares
Cash Flow Statement
Daily Values
Growth Metrics
Income Statement
Others
Ratios

Relay Therapeutics (RLAY) Current Assets (2020 - 2025)

Relay Therapeutics (RLAY) has disclosed Current Assets for 6 consecutive years, with $578.3 million as the latest value for Q4 2025.

  • Quarterly Current Assets fell 28.54% to $578.3 million in Q4 2025 from the year-ago period, while the trailing twelve-month figure was $578.3 million through Dec 2025, down 28.54% year-over-year, with the annual reading at $578.3 million for FY2025, 28.54% down from the prior year.
  • Current Assets for Q4 2025 was $578.3 million at Relay Therapeutics, down from $624.0 million in the prior quarter.
  • The five-year high for Current Assets was $1.1 billion in Q3 2022, with the low at $578.3 million in Q4 2025.
  • Average Current Assets over 5 years is $806.7 million, with a median of $789.7 million recorded in 2023.
  • The sharpest move saw Current Assets skyrocketed 115.69% in 2021, then decreased 28.54% in 2025.
  • Over 5 years, Current Assets stood at $976.2 million in 2021, then rose by 4.43% to $1.0 billion in 2022, then fell by 24.46% to $770.1 million in 2023, then grew by 5.08% to $809.2 million in 2024, then fell by 28.54% to $578.3 million in 2025.
  • According to Business Quant data, Current Assets over the past three periods came in at $578.3 million, $624.0 million, and $680.4 million for Q4 2025, Q3 2025, and Q2 2025 respectively.